FDA wants label changes for certain ADHD drugs

06/29/2005 | MarketWatch

The agency, expressing concerns about hallucinations, suicidal thoughts and psychotic and violent behavior associated with methylphenidate products, says it plans to make labeling changes for that class of drugs used to treat attention deficit hyperactivity disorder. Those include Johnson & Johnson's Concerta and Ritalin from Novartis. The agency said it also is reviewing adverse event reports on Eli Lilly's Strattera and Shire's Adderall. Company representatives were not available for comment.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA